AstraZeneca Investor Day Presentation Deck
Enhertu: an extensive clinical development programme
Focusing on HER2+ and HER2-low breast cancer and other cancers
24
Breast cancer
Gastric
cancer
Lung, CRC and
other cancers
HER2+
HER2 Low
HER2+
HER2 mutated
HER2 expressing
Post-neoadjuvant/
Adjuvant
DESTINY-Breast05 Ph III
1st line
DESTINY-Breast07 Ph Ib/II (Part 2)
DESTINY-Breast09 Ph III
BEGONIA Ph II
DESTINY-Lung04 Ph III
DESTINY-Lung03 Ph Ib
DESTINY-Breast03 Ph III
2nd line
DESTINY-Breast06 Ph III
DESTINY-Breast08 Ph lb
DESTINY-Gastric03 Ph lb/Il
DESTINY-Gastric02 Ph II
DESTINY-Gastric04 Ph III
DESTINY-Lung02 Ph II
DESTINY-PanTumor01 Ph II
DESTINY-Lung01 Ph II
HUDSON Ph II
DESTINY-PanTumor02 Ph II
3rd line+
DESTINY-Breast01 Ph II
DESTINY-Breast02 Ph III
DESTINY-Breast07 Ph Ib/II (Part 1)
DESTINY-Breast04 Ph III
DESTINY-Gastric01 Ph II
DESTINY-Gastric06 Ph II
DESTINY-CRC01 Ph II
DESTINY-CRC02 Ph II
monotherapy combination
3View entire presentation